Kyto Biopharma, Inc.

Kyto Biopharma, Inc. (Kyto) is a biopharmaceutical company engaged in the research and development of minimally toxic and non-immunosuppressive proprietary drugs for treating cancer, arthritis, and other proliferate and autoimmune diseases. It develops receptor-mediated technologies which target the vitamin B12 pathway, an essential cofactor needed for DNA synthesis in proliferating cells. Its products in development include receptor blocking monoclonal antibodies, transcobalamin blocking anti-receptor monoclonals and Si RNA based receptor modulation. Its antibody candidates are used to treat solid tumors such as colorectal and breast cancer. It licenses its patented antibody technologies to large pharmaceutical and biotechnology companies for the development of therapeutics which address large unmet market oppurtunities. The company is headquartered in Ontario, Canada.

Street: 
B1-114 Belmont Avenue
City: 
Toronto
Postcode: 
M5R 1P8
Federal State : 
Canada
WebSite: 
www.kytobiopharma.com

Company Index Score

Current Index Score Historical Index Score
  • Kyto Biopharma, Inc. currently scores 50 % in the index.
  • Kyto Biopharma, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Kyto Biopharma, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets